ASHP Releases Model MOUD Prescribing Legislation, State Protocol

Published: March 24, 2023

This week, ASHP released model legislation and a model protocol for pharmacists prescribing medications for opioid use disorder (MOUD).

Congress recently eliminated the X-waiver, a federal barrier to pharmacists prescribing MOUD. States can now use pharmacists to improve access to MOUD. ASHP has developed these models to encourage states to leverage pharmacists as part of the care team to curb the opioid crisis in their communities. 

The model legislation:

  • Provides clear authority for pharmacists to initiate MOUD
  • Establishes a timeline for board of pharmacy action
  • Ensures pharmacists comply with federal registration and training requirements
  • Removes any pre-existing state barriers to MOUD prescribing
  • Creates mechanisms for both Medicaid and commercial insurance to pay for these services

The model protocol similarly empowers pharmacists to initiate, modify, discontinue, and administer medications approved by the Food and Drug Administration for treatment of opioid use disorder.

The release of these models follows ASHP’s sustained advocacy on opioid use disorder last year, which resulted in the elimination of the X-waiver, along with continued efforts this year to expand access to MOUD. ASHP’s CEO Paul W. Abramowitz recently sent a letter to President Biden urging the federal government to utilize pharmacists to expand access to MOUD. ASHP will continue to advocate for and keep our members informed on this important issue.

For more advocacy resources and information, visit


Posted March 24, 2023

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information